Johnson & Johnson JNJCO
News
-
Preview — Barron's
-
Becton Dickinson to Invest $19 Billion in U.S. in Exchange for Tariff Relief — Update
-
J&J Says In-Development Blood-Cancer Treatment Shows Promise
-
Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint
-
Johnson & Johnson Gets FDA Approval for Imaavy to Treat Warm Autoimmune Hemolytic Anemia
-
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
-
Johnson & Johnson on Track for Record High Close — Data Talk
-
Johnson & Johnson On Pace for Record High Close — Data Talk
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 2.41B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 19.82
- Price/Sales
- 5.36
- Dividend Yield (Trailing)
- 2.43%
- Dividend Yield (Forward)
- 2.11%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 3.94%
Company Profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 140,800
- Website
- https://www.jnj.com
Competitors
Valuation
|
Metric
|
JNJCO
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 19.82 | 13.83 | 45.36 |
Price/Book Value | 6.57 | 6.58 | 8.57 |
Price/Sales | 5.36 | 4.89 | 5.43 |
Price/Cash Flow | 16.96 | 14.43 | 16.30 |
Price/Earnings
JNJCO
NVS
MRK
Financial Strength
|
Metric
|
JNJCO
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.73 | 0.55 | 0.71 |
Current Ratio | 1.09 | 0.86 | 1.32 |
Interest Coverage | 25.00 | 11.90 | 4.28 |
Quick Ratio
JNJCO
NVS
MRK
Profitability
|
Metric
|
JNJCO
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 13.42% | 14.74% | 6.27% |
Return on Equity (Normalized) | 32.69% | 39.06% | 16.68% |
Return on Invested Capital (Normalized) | 20.33% | 21.25% | 9.82% |
Return on Assets
JNJCO
NVS
MRK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|%!J&R&!! | LOCK|S? | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|G@^>t< | LOCK|@! | $630B | |||
| AbbVie Inc
ABBV
| LOCK|gr<Df^x | LOCK|%X | $489B | |||
| Merck & Co Inc
MRK
| LOCK|tt&H@C | LOCK|K#R | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|WqK&CVC | LOCK|Bz | $344B | |||
| Novartis AG ADR
NVS
| LOCK|&kqQ<#< | LOCK|V&# | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|>KbN?<?f | LOCK|sb | $244B | |||
| Amgen Inc
AMGN
| LOCK|<mnt^z&# | LOCK|><X | $224B | |||
| Gilead Sciences Inc
GILD
| LOCK|y$x#@H# | LOCK|@^s | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|#<qZ^M< | LOCK|$? | $169B |
United States